Stayble Therapeutics
G├╢teborg
About Stayble Therapeutics
Stayble Therapeutics is developing a minimally invasive injection-based treatment against chronic low back pain triggered by degenerative changes in the disc. Stayble’s treatment has the potential to offer a solution that may alleviate or abolish the pain without the need for surgery Behind Stayble Therapeutics stands an experienced, multidisciplinary team including a world-renowned back-pain researcher, experienced bio-entrepreneurs and former big pharma senior management. Their vision is that this treatment concept will reach out to millions of patients who are disabled by chronic back pain. We believe this drug has the potential to drastically reduce the suffering from a widespread, incapacitating condition.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $5.9M
- Funding stage: IPO
- Last round: Post-IPO Equity (May 2025)
- Ticker: sto:STABL
- Website: staybletherapeutics.com
- Phone: +46 730 808 397
Industries & Categories
Biotechnology, Health Care, Medical Device, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/stayble-therapeutics-2242289 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.